Mainz Biomed Reviews 2025 Achievements

Mainz Biomed N.V., a molecular genetics diagnostic company, highlighted its key accomplishments of 2025. These include the launch of eAArly DETECT 2, a U.S. feasibility study for its new colorectal cancer test involving 2,000 patients. The study aims to validate previous promising results. ColoAlert®, their DNA-based colorectal cancer test, gained approval for marketing in the UK and Switzerland, marking expansion in these regions.

In pancreatic cancer diagnostics, Mainz Biomed achieved significant milestones. A non-invasive pancreatic cancer screening test showed 100% sensitivity and 95% specificity in a feasibility study. The company also secured public funding from ISB, which will cover up to 50% of development costs, demonstrating significant governmental support.